- Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis : CLARIFY-MS study 6-month interim analysis2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study2023 | First Faculty of Medicine
- A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry2023 | First Faculty of Medicine
- Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence2023 | First Faculty of Medicine
- Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry2023 | First Faculty of Medicine
- Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Treatment of multiple sclerosis with oral cladribine: results of clinical trials2017 | First Faculty of Medicine
- Confirmed disability progression as a marker of permanent disability in multiple sclerosis2022 | First Faculty of Medicine